金沙制药兼并重组实证研究

【作者】 阎湧；

【导师】 廖进中；

【作者基本信息】 湖南大学 ， 工商管理， 2003， 硕士

【摘要】 制药行业是国内保持多年快速发展的朝阳行业，1978年至2000年，制药行业产值年均递增16.6％，成为国民经济中发展最快的行业之一。由于多年来的市场无序竞争和地方保护主义，制药行业普遍存在规模小、科研开发能力弱、主要以仿制生产为主的严重问题。为了加速中国由制药大国向制药强国的战略转变，应对加入WTO后跨国制药企业的竞争，制药企业必须立足国情，加强相互之间的分工合作，通过制药企业间的兼并重组，发展大集团、大公司，或做大做强，或做奇做精，主动拓展新形势下的生存空间。由于市场瞬息万变，制药企业兼并重组的方式往往是多元的，即多种方式的混合使用。如在“强强联合”后再“大吃小”，以迅速实现企业市场垄断地位提高的目标。如“三九集团”收购“雅安三九”“长征制药”；“哈药集团”参股“慈航制药”；“太太药业”收购“丽珠集团”等等。可以预见，为应对加入WTO后跨国制药集团的竞争，我国制药企业进行兼并重组是必然趋势，也是抗击全球经济一体化市场风浪的最终出路。 本文以白沙集团下属企业“珠海金沙(湖南)制药有限公司(以下简称金沙制药)”的兼并重组实例为标的进行实证研究，探讨和寻求我国制药行业兼并重组的模式和对策。更多还原

【Abstract】 Pharmacy trade is a domestic fast-developing vigorous trade for many years. From 1978 to 2002, the output value of pharmacy trade increased progressively 16.6% every year and became one of trades with the fastest developing speed in national economy. Because of the unordered competition of market for many years and local protectionism, there are serious problems for most pharmacy trade, such as small scales of enterprises, weak capacity for research and developing and taking model production mainly. In order to accelerate the strategic change of China from the pharmaceutical big country to powerful country and meet the competition of the international pharmacy enterprises after the accession to WTO, pharmacy trade must base on the national conditions to strengthen the division and cooperation and through merger and recombination among pharmacy enterprises to develop the big group or big company to make it strongly or greatly or very precisely and expand the living space under the new situation on the new situation. Because the market changes fast, the ways for merger and recombination of pharmacy enterprises are often plural, many kinds of ways are used. For example, "eats small one "after" combination among the strong ones", so as to realize those monopolizing goal whose status are raised by market rapidly. Such as" San Jiu Group" purchases" Yaan San Jiu and Long March Pharmaceutical Co.,Ltd."," Hayao Group" participates in "Hachi Pharmaceutical Co.,Ltd." by shares; "Taitai Pharmaceutical Co.,Ltd. "purchases" Livzou Group", etc. We could predict that, in order to deal with the competition of international pharmaceutical groups after the accession to WTO, it is an inexorable trend that pharmacy trade of our country merges and recombines. It is the final outlet of resisting stormy waves of market of global economic integration too.This paper uses the merger and recombination this text instance of Zhuhai Jinsa(Hunan) pharmaceutical Co., Ltd.(hereafter referred to as Jinsa pharmacy) (belongs to Beshiney Group) to go on the real research and try to probe into and seek the modes and countermeasures merged and recombined in the pharmacy trade of our country.更多还原